New, Less Toxic Therapy For Stage-4 Breast Cancer
For women suffering from stage-4 breast cancer, there is a new treatment plan that, according to a recent Northwestern Medicine clinical trial, is highly effective and has minimal toxicity. The treatment includes a drug recently approved by the US Food and Drug Administration. ... Read News
International Myeloma Working Group Updated Criteria For The ...
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Lancet Oncology, 15 (2014) e538-e548. doi:10.1016/S1470-2045(14)70442-5 ... Read Content
Lancet Oncol 3
For personal use. Only reproduce with permission from The Lancet Publishing Group. THE LANCET Oncology Vol 3 September 2002 http://image.thelancet.com/extras/01ONCL1006webref.pdf ... Read Here
Cancer Control In Latin America And The Caribbean - YouTube
Published: 26 April 2013 Latin America is facing an alarming increase in cancer incidence, and unless urgent action is taken to prevent the disease, published in The Lancet Oncology. ... View Video
Review GFP Imaging In Vivo - MetaMouse
546 THE LANCET Oncology Vol 3 September 2002 http://oncology.thelancet.com We have developed a way of imaging metastases in mice by use of tumour cells expressing green fluorescent protein (GFP) that can be used to examine fresh tissue, ... Doc Retrieval
Your radiation oncology team will carefully plan your treatment, based on your diagnosis and the size, shape, and location of your target area. The Lancet Oncology, Volume 7, Issue 10, Pages 848 - 858, October 2006. Overview Of Image-Guided Radiation Therapy. ... Read Article
High-quality Cancer Diagnosis For Resource-poor Locations
Title: High-quality cancer diagnosis for resource-poor locations Author: John Maurice Subject: Lancet Oncology, 13 (2015) . doi:10.1016/S1470-2045(15)70186-5 ... Document Viewer
Organised By Elsevier, Organisation For Oncology And ...
Organised by Elsevier, Organisation for Oncology and Translational Research, The Lancet Oncology, and The Lancet Infectious Diseases Emend Update - Sponsored Symposium by Merck Sharp and Dohme Novel oral HCV therapies - The era of direct acting antiviral agents - ... Retrieve Here
Circulating Tumor Cells May Predict Prognosis In Early Breast ...
Download from iTunes: http://itunes.apple.com/us/itunes-u/c. A study published in the June Lancet Oncology reports early stage breast cancer patients who produce circulating tumor cells (CTC) may be at greater risk for breast cancer recurrence. Until now, lymph node biopsy has been ... View Video
Purged Versus Non-purged Peripheral Blood Stem-cell ...
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial Lancet Oncology, 14 (2013) 999-1008. doi:10.1016/S1470-2045(13)70309-7 Created Date: ... Read Document
Regulatory And Clinical Considerations For Biosimilar ...
Regulatory and clinical considerations for biosimilar oncology drugs Charles L Bennett, Brian Chen, Terhi Hermanson, Michael D Wyatt, Richard M Schulz, Lancet Oncol 2014; 15: e594–605 The Southern Network on Adverse Reaction (SONAR) ... Return Doc
Retraction - Wikipedia, The Free Encyclopedia
A retraction is a public statement made about an earlier statement that withdraws, cancels, refutes, or reverses the original statement or ceases and desists from publishing the original statement. The Lancet Oncology 8 (12): 1071–8. ... Read Article
Lancet Oncology Instructions Authors - Tickletduckme
Lancet Oncology Instructions Authors Manuscripts should be submitted online via the The Lancet Oncology's online Simply log on to EES and follow the onscreen instructions for all submissions. ... Doc Viewer
Newsdesk - Center For Science In The Public Interest
4 THE LANCET Oncology Vol 4 January 2003 http://oncology.thelancet.com Newsdesk In February 2002, Barry Castleman, an environmental consultant from Baltimore, MD, USA sent Gro Harlem Brundtland, Director General of the World Health Organization (WHO), a ... Access Full Source
Lancet Oncology Author Instructions - Ralgelila
Lancet Oncology Author Instructions Manuscripts should be submitted online via the The Lancet Oncology's online Simply log on to EES and follow the onscreen instructions for all submissions. ... View This Document
Panitumumab - Wikipedia, The Free Encyclopedia
Panitumumab , formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). ... Read Article
MY LETTER TO LANCET ONCOLOGY - Tobaccoharmreduction.org
I have appended below a letter I sent to the editor of Lancet Oncology about this same conflict of interest. It goes into more detail about the situation. ... Read Here
Lung Adenocarcinoma - Symptoms, Treatment, And Prognosis
Lung adenocarcinoma is the most common type of lung cancer. What are the symptoms, treatments and prognosis? ... Read Article
Carcinogenicity Of Tetrachlorvinphos, Parathion, Malathion ...
Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate In March, 2015, 17 experts from 11 countries met at the International Lancet Oncology, 13 (2015) . doi:10.1016/S1470-2045(15)70134-8 Created Date: ... View Full Source
Hyperthermia In Cancer Treatment Review - UTHealth
Hyperthermia in cancer treatment Review Hyperthermia, the procedure of raising the temperature of tumour-loaded tissue to 40–43°C, 490 THE LANCET Oncology Vol 3 August 2002 http://oncology.thelancet.com Review Hyperthermia in cancer treatment ... Read Content
Trametinib For Patients With Advanced Melanoma – Authors' Reply
Trametinib for patients with advanced melanoma Gerald Falchook and colleagues1 show clinical activity of the MEK inhibitor trametinib in patients with Lancet Oncology, 13 (2012) e409-e410. doi:10.1016/S1470-2045(12)70429-1 Created Date: ... Retrieve Content
Lancet Oncology Instructions To Authors
Current United State guidelines recommend that women 30 to 65 years undergo The author of an editorial in Lancet Oncology argued that a 1 in 400 risk. ... Access Full Source
FDA Accepts Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) In Advanced Non-Small Cell ...
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review a new supplemental Biologics License Application for KEYTRUDA® , the company’s anti-PD-1 therapy, to include data from KEYNOTE-010. ... Read News
La Vacuna Contra VPH Protege Contra Cáncer Cervical
, The Lancet Oncology, junio 10, 2015. Programa de Vigilancia, Epidemiología y Resultados Finales (SEER, por las siglas en Inglés), "Estadísticas del cáncer de cuello uterino por raza/etnicidad,” (en Inglés) (Visitado 13 de junio de 2015) ... Read Article
Anthroposophic Medicine - Wikipedia, The Free Encyclopedia
Anthroposophic medicine (or anthroposophical medicine) is a form of alternative medicine. [1] A 2013 article on mistletoe in Lancet Oncology invoked Ben Goldacre's observation that a geographical preference for certain therapies was a hallmark of quackery, ... Read Article
Author Statements - The Lancet
Author statements Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. I agree with: the plan to submit to The Lancet Oncology; the contents of the manuscript; to being listed as an author; and to the ... Return Doc
Drug Combination Slows Breast Cancer Spread
A combination of two drugs delays progression of advanced, aggressive breast cancer by an average of nine months -- working in all subsets of the most common type of breast cancer. The combination -- of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant -- slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast ... Read News
No comments:
Post a Comment